2 completed, 1 suspended. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Suspended 1 |
Follow ADHD - Combined Type: new trials by email Literature Review of ADHD - Combined Type trials Research Report on ADHD - Combined Type
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) - ADHD, Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Cingulate Therapeutics | 103 | 2023-08-01 | 2026-01-22 |
| Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg - ADHD, ADHD - Combined Type | Phase 3 | Suspended | Cingulate Therapeutics | 45 | 2023-07-31 | 2026-05-05 |
| Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg - ADHD, ADHD - Combined Type | Phase 3 | Completed | Cingulate Therapeutics | 26 | 2022-12-29 | 2026-07-02 |
Attention Deficit Disorder with Hyperactivity (3)
Attention Deficit and Disruptive Behavior Disorders (3) · Mental Disorders (3) · Neurodevelopmental Disorders (3)
Dexmethylphenidate Hydrochloride (1) · Double-Blind Method (1) · Random Allocation (1)
United States (3)
Ann Childress, MD (2) · Matt Brams, MD (2)